NI201400111A - Tratamiento del cáncer con inhibidores tor cinasa - Google Patents

Tratamiento del cáncer con inhibidores tor cinasa

Info

Publication number
NI201400111A
NI201400111A NI201400111A NI201400111A NI201400111A NI 201400111 A NI201400111 A NI 201400111A NI 201400111 A NI201400111 A NI 201400111A NI 201400111 A NI201400111 A NI 201400111A NI 201400111 A NI201400111 A NI 201400111A
Authority
NI
Nicaragua
Prior art keywords
tor kinase
kinase inhibitors
cancer treatment
neck
head
Prior art date
Application number
NI201400111A
Other languages
English (en)
Spanish (es)
Inventor
Xu Shuichan
Mae Hege Kristen
Raymon Heather
Loraine Wong Lilly
Original Assignee
Signal Pharm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signal Pharm Llc filed Critical Signal Pharm Llc
Publication of NI201400111A publication Critical patent/NI201400111A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NI201400111A 2012-03-15 2014-09-12 Tratamiento del cáncer con inhibidores tor cinasa NI201400111A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261611361P 2012-03-15 2012-03-15
US201261715323P 2012-10-18 2012-10-18

Publications (1)

Publication Number Publication Date
NI201400111A true NI201400111A (es) 2015-01-15

Family

ID=48014336

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201400111A NI201400111A (es) 2012-03-15 2014-09-12 Tratamiento del cáncer con inhibidores tor cinasa

Country Status (21)

Country Link
US (1) US20130245026A1 (https=)
EP (1) EP2825170B1 (https=)
JP (3) JP2015510891A (https=)
KR (3) KR20200070416A (https=)
CN (2) CN104519885A (https=)
AU (1) AU2013203153B2 (https=)
BR (1) BR112014022703A2 (https=)
CA (1) CA2866872A1 (https=)
EA (1) EA028414B1 (https=)
ES (1) ES2677874T3 (https=)
IL (1) IL234602B (https=)
MX (1) MX360878B (https=)
MY (1) MY174022A (https=)
NI (1) NI201400111A (https=)
NZ (1) NZ628416A (https=)
PH (1) PH12014502029B1 (https=)
SG (1) SG11201405707XA (https=)
TW (1) TWI583385B (https=)
UA (1) UA114315C2 (https=)
WO (1) WO2013138557A1 (https=)
ZA (1) ZA201406706B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014022703A2 (pt) * 2012-03-15 2021-05-04 Signal Pharmaceuticals, Llc método para o tratamento de carcinoma de células escamosas de cabeça e de pescoço, método para melhorar os critérios de avaliação, método para inibição da fosforilação, método para inibição de dna, método para a medição da inibição da fosforilação, kit
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
PE20151995A1 (es) 2013-01-16 2016-01-13 Signal Pharm Llc Compuestos sustituidos de pirrolopirimidina, composiciones de los mismos, y metodos de tratamiento con los mismos
US9630966B2 (en) 2013-04-17 2017-04-25 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
CN105377299B (zh) 2013-04-17 2018-06-12 西格诺药品有限公司 用于治疗前列腺癌的包含二氢吡嗪并-吡嗪化合物和雄激素受体拮抗剂的组合疗法
CA2908742C (en) * 2013-04-17 2021-06-01 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
WO2014172436A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
TW201526894A (zh) * 2013-04-17 2015-07-16 Signal Pharm Llc 藉二氫吡并吡治療癌症
US9505764B2 (en) 2013-04-17 2016-11-29 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
CA2909579A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer
CA2909629C (en) 2013-04-17 2022-12-13 Signal Pharmaceuticals, Llc Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
NZ629486A (en) 2013-05-29 2017-11-24 Signal Pharm Llc Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
US9512129B2 (en) 2014-04-16 2016-12-06 Signal Pharmaceuticals, Llc Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
ES2823756T3 (es) 2014-04-16 2021-05-10 Signal Pharm Llc Métodos para tratar el cáncer usando terapia de combinación de inhibidores de quinasa TOR
WO2016010886A1 (en) 2014-07-14 2016-01-21 Signal Pharmaceuticals, Llc Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
TWI787284B (zh) 2017-06-22 2022-12-21 美商西建公司 以b型肝炎病毒感染表徵之肝細胞癌之治療

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2666624C (en) 2006-10-19 2015-12-29 Signal Pharmaceuticals, Llc Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors
MX337906B (es) * 2006-10-19 2016-03-28 Signal Pharm Llc Compuestos de heteroarilo, composiciones de los mismos, y su uso como inhibidores de proteina cinasas.
US20110200556A1 (en) * 2008-08-20 2011-08-18 The United States Of America, As Represented By Th E Secretary, Department Of Health And Human Servi Chemoprevention of head and neck squamous cell carcinomas
US8110578B2 (en) * 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
SG10201500511TA (en) 2009-10-26 2015-03-30 Signal Pharm Llc Methods Of Synthesis And Purification Of Heteroaryl Compounds
US20120028972A1 (en) * 2010-07-30 2012-02-02 Lilly Wong Biomarker assays for detecting or measuring inhibition of tor kinase activity
BR112014022703A2 (pt) * 2012-03-15 2021-05-04 Signal Pharmaceuticals, Llc método para o tratamento de carcinoma de células escamosas de cabeça e de pescoço, método para melhorar os critérios de avaliação, método para inibição da fosforilação, método para inibição de dna, método para a medição da inibição da fosforilação, kit

Also Published As

Publication number Publication date
UA114315C2 (uk) 2017-05-25
KR102122617B1 (ko) 2020-06-12
CN104519885A (zh) 2015-04-15
CA2866872A1 (en) 2013-09-19
BR112014022703A2 (pt) 2021-05-04
IL234602A0 (en) 2014-11-30
JP2015510891A (ja) 2015-04-13
WO2013138557A1 (en) 2013-09-19
MY174022A (en) 2020-03-04
KR20140138927A (ko) 2014-12-04
KR20210071101A (ko) 2021-06-15
SG11201405707XA (en) 2014-10-30
EP2825170A1 (en) 2015-01-21
PH12014502029A1 (en) 2014-11-24
ES2677874T3 (es) 2018-08-07
JP2021102637A (ja) 2021-07-15
NZ628416A (en) 2016-04-29
ZA201406706B (en) 2016-05-25
US20130245026A1 (en) 2013-09-19
TWI583385B (zh) 2017-05-21
EA028414B1 (ru) 2017-11-30
JP2019108368A (ja) 2019-07-04
MX360878B (es) 2018-11-21
EA201491699A1 (ru) 2015-02-27
AU2013203153A1 (en) 2013-10-03
PH12014502029B1 (en) 2014-11-24
HK1201750A1 (en) 2015-09-11
MX2014011077A (es) 2014-10-14
EP2825170B1 (en) 2018-05-09
AU2013203153B2 (en) 2015-09-03
IL234602B (en) 2020-05-31
CN108992446A (zh) 2018-12-14
KR20200070416A (ko) 2020-06-17
TW201343168A (zh) 2013-11-01

Similar Documents

Publication Publication Date Title
NI201400111A (es) Tratamiento del cáncer con inhibidores tor cinasa
NI201400109A (es) Tratamiento del cáncer con inhibidores tor cinasa
NI201400110A (es) Tratamiento del cáncer con inhibidores tor cinasa
CL2015002530A1 (es) Inhibidores de cdc7
CR20150376A (es) Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos
NI201400095A (es) Metodos para el tratamiento del cáncer de pulmon de celulas no pequeñas utilizando terapia combinada de inhibidor tor cinasa.
ECSP17013903A (es) Protein kinase c inhibitors and methods of their use
MX2015014596A (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto imid para tratar cancer.
CR20170352A (es) Terapias de combinación para el tratamiento de cánceres
NI201400112A (es) Tratamiento del cáncer con inhibidores tor cinasa
MX385122B (es) Uso de ibrutinib en el tramiento de enfermedad injerto contra huésped crónica.
CL2015002807A1 (es) Terapia de combinación
MX368286B (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto de quinazolinona 5-sustituida para tratar cancer.
CR20160308A (es) Combinaciones de inhibidores de histona deacetilasa y farmacos inmunomoduladores
MX2015014599A (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tracar cancer.
CL2017000050A1 (es) Terapia de combinación para el cáncer
MX2015014589A (es) Tratamiento de cancer con dihidropirazino-pirazinas.
NI201500055A (es) Tratamiento de cáncer de próstata con inhibidores de quinasa tor
MX2016002307A (es) Tratamiento para el cancer.
CR20140480A (es) Metodos para tratar el cancer usando inhibidor de pi3k e inhibidor de mek
DOP2017000174A (es) Terapias de combinación para el tratamiento de cánceres
EA201491695A1 (ru) Лечение рака ингибиторами tor-киназы